How Triple Agonism Differs Pharmacologically The research appeal of triple agonists like retatrutide lies in the combination of three biological effects: GLP-1 receptor activation: Increased insulin secretion (glucose-dependent), reduced glucagon secretion, delayed gastric emptying, appetite reduction
But the FDA has never approved phentermine for long-term continuous use, and the data supporting extended protocols is thin
The dual mechanism gives it an edge in patients without diabetes in particular
For some people, pursuing weight loss can be harmful, for instance by leading to weight cycling or increasing the risk of developing an eating disorder
After you sign up, a Maximus doctor will review your medical history and determine whether Tirzepatide or Semaglutide is safe and appropriate for you
The GLP-1 and GIP tolerance you built on tirzepatide is relevant, but the glucagon component is a wild card